Vancouver, Canada – April 16, 2026 Augurex Life Sciences Corp., a leader in the development of autoimmune diagnostic tests, today announced it will attend and exhibit at the Congress of Clinical Rheumatology (CCR) East 2026, taking place April 30 to May 3 in Destin, Florida.
The Congress of Clinical Rheumatology brings together community rheumatology providers to explore advances in clinical care and diagnostic innovation. Augurex will showcase its biomarker-driven diagnostic solutions designed to support earlier identification and more informed decision-making in inflammatory arthritis.
The company’s diagnostic solutions include:
- JOINTstat® (14-3-3eta), a modifiable biomarker that complements RF and anti-CCP to improve diagnostic confidence, support prognosis and risk assessment, and enable ongoing monitoring in rheumatoid arthritis.
- SPINEstat® (Anti-14-3-3eta Multiplex), a first-in-class diagnostic biomarker for axial spondyloarthritis that supports earlier and more accurate detection, helps differentiate inflammatory disease from mechanical back pain, and complements established markers including CRP and HLA-B27.
Augurex looks forward to engaging with clinicians and partners to discuss how biomarker-based approaches can enhance clinical assessment and support improved patient outcomes in routine rheumatology practice.
Attendees are invited to visit Augurex at Booth 64 during the conference.
For more information or to schedule a meeting, please contact nmazinani@augurex.com.
About Augurex
Augurex is a commercial-stage diagnostics company dedicated to the early identification and diagnosis of autoimmune disorders, allowing treatment options to be optimized and personalized for patients around the world. Augurex’s 14-3-3eta blood test, available as JOINTstat® in Canada and in Great Britain, is an important tool in the diagnosis and management of rheumatoid arthritis. Analyte-specific reagents to detect 14-3-3eta are available for purchase and use by U.S. clinical laboratories as a component of diagnostic tests developed by such laboratories. The Anti-14-3-3eta Multiplex test, approved as SPINEstat® in Canada and Great Britain, expands Augurex’s portfolio of autoimmune diagnostic solutions into axial spondyloarthritis, an autoimmune disease often misdiagnosed as low back pain, which if untreated, can lead to impaired spinal mobility and fusion of the vertebrae. Learn more about Augurex at www.augurex.com and follow us on Facebook, LinkedIn, and X.